A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

被引：10
|
作者：
Kaddoura, Rasha [1 ]
Dabdoob, Wafer A. A. [1 ]
Ahmed, Khalid [1 ]
Yassin, Mohamed A. A. [1 ]
机构：
[1] Hamad Med Corp, Doha, Qatar
来源：
FRONTIERS IN MEDICINE | 2023年 / 10卷
关键词：
chronic myeloid leukemia; tyrosine kinase; heart failure; pulmonary arterial hypertension; QT prolongation; dasatinib; ponatinib; pleural effusion; MAJOR MOLECULAR RESPONSE; CHRONIC PHASE; CARDIOVASCULAR EVENTS; NILOTINIB; IMATINIB; HYPERTENSION; POPULATION; MANAGEMENT; DASATINIB; SAFETY;
D O I：
10.3389/fmed.2023.1163137
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.
引用
收藏
页数：19
相关论文
共 50 条
  • [41] Vascular complications in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    Cho, Hee Jeong
    Sohn, Sang-Kyun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (04): : 224 - 233
  • [42] New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    Almeida, Ana G.
    Almeida, Antonio
    Melo, Teresa
    Guerra, Lurdes
    Lopes, Luis
    Ribeiro, Patricia
    Duarte, Marta
    Mota, Alexandra
    Fontes-Carvalho, Ricardo
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2019, 38 (01) : 1 - 9
  • [43] Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors
    Hefner, Jochen
    Csef, Eva-Johanna
    Kunzmann, Volker
    ONCOLOGY NURSING FORUM, 2016, 43 (02) : 190 - 197
  • [44] Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors
    Mauro M.J.
    Current Treatment Options in Oncology, 2007, 8 (4) : 287 - 295
  • [45] A Chemical Approach to Overcome Tyrosine Kinase Inhibitors Resistance: Learning from Chronic Myeloid Leukemia
    Zanforlin, Enrico
    Zagotto, Giuseppe
    Ribaudo, Giovanni
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (33) : 6033 - 6052
  • [46] Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors
    Veltmaat, Lukas
    Cortes, Jorge
    BLOOD, 2024, 143 (10) : 858 - 865
  • [47] Efficacy and safety of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: a meta-analysis
    Xie, Bingqian
    Gao, Minjie
    Hu, Liangning
    Kong, Yuanyuan
    Gao, Lu
    Wang, Houcai
    Yang, Guang
    Zhang, Yiwen
    Tao, Yi
    Xu, Hongwei
    Zhan, Fenghuang
    Wu, Xiaosong
    Shi, Jumei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 1815 - 1821
  • [48] Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
    Assuncao, Paola Morelato
    Lana, Tamires Prates
    Delamain, Marcia Torresan
    Duarte, Gislaine Oliveira
    Zulli, Roberto
    Lorand-Metze, Irene
    de Souza, Carmino Antonio
    de Paula, Erich Vinicius
    Barbosa Pagnano, Katia Borgia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (03) : 162 - 166
  • [49] Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
    Tan, Bee Kim
    Chong, Ping
    Chua, Siew Siang
    Chen, Li-Chia
    PATIENT PREFERENCE AND ADHERENCE, 2021, 15 : 2563 - 2575
  • [50] Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy
    Mohamed A. M. Ali
    Molecular Diagnosis & Therapy, 2016, 20 : 315 - 333
12345